Concurrent chemoradiotherapy versus radiotherapy alone for stage II nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy

Background Concurrent chemoradiotherapy has long been a standardized therapy for localized advanced nasopharyngeal cancer. It is widely used in clinical applications. In contrast, NCCN guidelines highlight that the efficacy of concurrent chemoradiotherapy for stage II nasopharyngeal cancer in the ne...

Full description

Saved in:
Bibliographic Details
Published in:European archives of oto-rhino-laryngology 2023-07, Vol.280 (7), p.3097-3106
Main Authors: Xue, Yongyuan, Li, Guoping, Xie, Tao, Xu, Hongyang, Xu, Tianrui, Li, Zhengfei, Zhu, Lixiu, Li, Xin, Li, Zhiyao, Xiong, Wei
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Chemoradiotherapy
Disease-Free Survival
Head and Neck Surgery
Humans
Medicine
Medicine & Public Health
Nasopharyngeal Carcinoma - pathology
Nasopharyngeal Neoplasms - pathology
Neurosurgery
Otorhinolaryngology
Radiotherapy, Intensity-Modulated
Retrospective Studies
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Concurrent chemoradiotherapy has long been a standardized therapy for localized advanced nasopharyngeal cancer. It is widely used in clinical applications. In contrast, NCCN guidelines highlight that the efficacy of concurrent chemoradiotherapy for stage II nasopharyngeal cancer in the new era of intensity-modulated radiotherapy has not been defined. Thus, we systematically reviewed the significance of concurrent chemoradiotherapy for stage II nasopharyngeal cancer. Methods We searched the relevant literature in PubMed, EMBASE, and Cochrane, extracting relevant data from the searched literature. The main items extracted were hazard ratios (HRs), risk ratios (RRs) and 95% confidence intervals (CIs). When the HR could not be extracted from the literature, we used Engauge Digitizer software for extraction. Data analysis was accomplished using the Review Manager 5.4 tool. Results Our study included seven articles involving 1633 cases of stage II nasopharyngeal cancer. The survival outcomes were overall survival (OS) (HR = 1.03, 95% CI (0.71–1.49), P = 0.87), progression-free survival (PFS) (HR = 0.91, 95% CI (0.59–1.39), P = 0.66), distant metastasis-free survival (DMFS) (HR = 1.05, 95% CI (0.57–1.93), P = 0.87), local recurrence-free survival (LRFS) (HR = 0.87, 95% CI (0.41–1.84), P = 0.71, P > 0.05), and locoregional failure-free survival (LFFS) (HR = 1.18, 95% CI (0.52–2.70), P = 0.69). Conclusions In the era of intensity-modulated radiotherapy, concurrent chemoradiotherapy and radiotherapy alone have the same survival benefits, and concurrent chemoradiotherapy increases acute hematological toxicity. Subgroup analysis showed that for people with N1 nasopharyngeal cancer at risk of distant metastases, concurrent chemoradiotherapy and radiotherapy alone also had equal survival benefits.
ISSN:0937-4477
1434-4726
DOI:10.1007/s00405-023-07943-9